Segal Trials to test Mind Medicine, Inc.'s MM-120, a proprietary, pharmaceutically optimized form of lysergic acid diethylamide (LSD), in Phase II human trial.
MIAMI, Aug. 30, 2022 /PRNewswire-PRWeb/ -- Segal Trials, a privately held network of clinical research sites throughout South Florida, announced that its' investigators and the site are the first in the United States to conduct a large, randomized clinical trial to investigate MM-120 (LSD D-tartrate), for the treatment of Generalized Anxiety Disorder (GAD). Segal Trials' investigators administered the first dose of MM-120 to a study participant on August 24th at The Center for Psychedelic and Cannabis Research in Miami, FL.
Dr. Rishi Kakar, Medical Director and Chief Scientific Officer at Segal Trials, serves as a Principal Investigator for the MM-120 trial, which is a randomized, double-blind, parallel-group design study to evaluate the potential effectiveness of MM-120 in patients with GAD.
"MindMed's compound has the potential to change the way clinicians treat GAD," said Dr. Kakar. "Certainly, conducting the first trial of its kind in the nation puts our companies at the forefront of psychedelic pharmacological research."
Dr. Kakar and his team will conduct the trial at Segal's Center for Psychedelic and Cannabis Research, which was specifically built to create a structured inpatient environment that ensures patient safety and comfort.
About Generalized Anxiety Disorder (GAD)
GAD is a chronic, often debilitating mental health disorder that affects approximately 6% of U.S. adults in their lifetimes. Symptoms of GAD include excessive anxiety and worry that persists for over six months, which can lead to significant impairments in social, occupational and other functioning, according to the National Institute of Mental Health (NIMH). While there is substantial diagnostic overlap between GAD, Major Depressive Disorder (MDD) and other major mental health disorders, there has been very little innovation focused on the treatment of GAD in the past several decades due to the shift in focus from anxiety disorders like GAD toward depressive disorders like MDD, driven by the marketing of serotonin reuptake inhibitors starting in the 1990s.
About Segal Trials
Segal Trials, founded in 1998, is a privately held network of research sites throughout South Florida conducting Phase I-IV research trials that have led to 54 FDA-approved medications and devices. The company's trials focus on psychiatry, neurology, addiction, insomnia, infectious diseases, vaccine development, and women's health; and it runs trials in outpatient, inpatient, PSG, and residential care facility settings.
For more information about Segal Trials, or to schedule an interview, please contact Meieli Sawyer at [email protected].
About MindMed
MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. The company is developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.
For Media, email [email protected]; for Investors, email [email protected].
Media Contact
Meieli Sawyer, The Weinbach Group, 305-668-0070, [email protected]
SOURCE Segal Trials
Share this article